ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
出版年份 2013 全文链接
标题
ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
作者
关键词
-
出版物
EUROPEAN JOURNAL OF ENDOCRINOLOGY
Volume 169, Issue 6, Pages R153-R164
出版商
Bioscientifica
发表日期
2013-09-04
DOI
10.1530/eje-13-0434
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab
- (2013) Jeffrey S. Weber et al. CANCER
- Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)
- (2013) Salvatore Maria Corsello et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
- (2013) Salvatore Maria Corsello et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Monoclonal antibody therapeutics: history and future
- (2012) Nicholas APS Buss et al. CURRENT OPINION IN PHARMACOLOGY
- MECHANISMS IN ENDOCRINOLOGY: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review
- (2012) A. Juszczak et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Ravi A Madan et al. LANCET ONCOLOGY
- Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
- (2012) Anna Maria Di Giacomo et al. LANCET ONCOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Marketed therapeutic antibodies compendium
- (2012) Janice M. Reichert mAbs
- Immunotherapies in Rheumatologic Disorders
- (2012) Anne V. Miller et al. MEDICAL CLINICS OF NORTH AMERICA
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypophysitis Induced by Monoclonal Antibodies to Cytotoxic T Lymphocyte Antigen 4: Challenges from a New Cause of a Rare Disease
- (2012) F. Torino et al. ONCOLOGIST
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety
- (2011) Gert Van Assche et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Association of Ipilimumab Therapy for Advanced Melanoma with Secondary Adrenal Insufficiency: A Case Series
- (2011) Le Min et al. Endocrine Practice
- Use of monoclonal antibodies in renal transplantation
- (2011) Martijn WF van den Hoogen et al. Immunotherapy
- Thyroid Dysfunction from Antineoplastic Agents
- (2011) O.-P. R. Hamnvik et al. JNCI-Journal of the National Cancer Institute
- Hyponatremia associated with Ipilimumab-induced hypophysitis
- (2011) Zachary R. Barnard et al. MEDICAL ONCOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
- (2011) Pieranna Chiarella Recent Patents on Anti-Cancer Drug Discovery
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
- (2010) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
- (2010) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
- (2010) A. A. Sarnaik et al. CLINICAL CANCER RESEARCH
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade
- (2010) Peter Boasberg et al. SEMINARS IN ONCOLOGY
- The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications
- (2010) Anna Maria Di Giacomo et al. SEMINARS IN ONCOLOGY
- Ipilimumab-Induced Hypophysitis: MR Imaging Findings
- (2009) K.J. Carpenter et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
- (2009) S. M. Ansell et al. CLINICAL CANCER RESEARCH
- Management and interpretation of novel toxicities of molecular targeted therapies: Renal toxicities
- (2009) Joan Carles et al. EUROPEAN JOURNAL OF CANCER
- Gastrointestinal toxicities of novel agents in cancer therapy
- (2009) Amani Asnacios et al. EUROPEAN JOURNAL OF CANCER
- Skin toxicities of targeted therapies
- (2009) Siegfried Segaert et al. EUROPEAN JOURNAL OF CANCER
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
- (2009) Troy Dillard et al. Pituitary
- Hypopituitarism following radiotherapy
- (2008) Ken H. Darzy et al. Pituitary
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now